Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 ...
The COVID-19 pandemic forced a number of changes, many of which will remain in place long after it subsides. One important but under-recognized shift could be in the field of clinical diagnostics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results